1
|
Experimental and computation studies of a Zn(II) coordination complex with isophthalic acid and benzimidazole as ligands. J Mol Struct 2023. [DOI: 10.1016/j.molstruc.2022.134290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
A comprehensive review on zinc(II) complexes as anti-diabetic agents: The advances, scientific gaps and prospects. Pharmacol Res 2020; 155:104744. [PMID: 32156651 DOI: 10.1016/j.phrs.2020.104744] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2019] [Revised: 12/22/2019] [Accepted: 03/03/2020] [Indexed: 12/15/2022]
Abstract
Zinc has gained notable attention in the development of potent anti-diabetic agents, due to its role in insulin storage and secretion, as well as its reported insulin mimetic properties. Consequently, zinc(II) has been complexed with numerous organic ligands as an adjuvant to develop anti-diabetic agents with improved and/or broader scope of pharmacological properties. This review focuses on the research advances thus far to identify the major scientific gaps and prospects. Peer-reviewed published data on the anti-diabetic effects of zinc(II) complexes were sourced from different scientific search engines, including, but not limited to "PubMed", "Google Scholar", "Scopus" and ScienceDirect to identify potent anti-diabetic zinc(II) complexes. The complexes were subcategorized according to their precursor ligands. A critical analysis of the outcomes from published studies shows promising leads, with Zn(II) complexes having a "tri-facet" mode of exerting pharmacological effects. However, the promising leads have been flawed by some major scientific gaps. While zinc(II) complexes of synthetic ligands with little or no anti-diabetic pharmacological history remain the most studied (about 72 %), their toxicity profile was not reported, which raises safety concerns for clinical relevance. The zinc(II) complexes of plant polyphenols; natural ligands, such as maltol and hinokitiol; and supplements, such as ascorbic acid (a natural antioxidant), l-threonine and l-carnitine, showed promising insulin mimetic and glycemic control properties but remain understudied and lack clinical validation, in spite of their minimal safety concerns and health benefits. A paradigm shift toward probing (including clinical studies) supplements, plant polyphenol and natural ligands as anti-diabetic zinc(II) complex is, therefore, recommended. Also, promising anti-diabetic Zn(II) complexes of synthetic ligands should undergo critical toxicity evaluation to address possible safety concerns.
Collapse
|
3
|
Kawano S, Yoshikawa Y, Kato A, Higashi S, Mitani K, Yasui H, Habata Y, Kuwahara S, Sasaki K, Saito R. Potential antidiabetic zinc(II) complexes of novel 5-oxo-2-thioxopyrrolidine derivatives synthesized via an unprecedented reaction. Tetrahedron Lett 2019. [DOI: 10.1016/j.tetlet.2019.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
4
|
Ranasinghe P, Pigera S, Galappatthy P, Katulanda P, Constantine GR. Zinc and diabetes mellitus: understanding molecular mechanisms and clinical implications. ACTA ACUST UNITED AC 2015; 23:44. [PMID: 26381880 PMCID: PMC4573932 DOI: 10.1186/s40199-015-0127-4] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 08/20/2015] [Indexed: 01/08/2023]
Abstract
Background Diabetes mellitus is a leading cause of morbidity and mortality worldwide. Studies have shown that Zinc has numerous beneficial effects in both type-1 and type-2 diabetes. We aim to evaluate the literature on the mechanisms and molecular level effects of Zinc on glycaemic control, β-cell function, pathogenesis of diabetes and its complications. Methods A review of published studies reporting mechanisms of action of Zinc in diabetes was undertaken in PubMed and SciVerse Scopus medical databases using the following search terms in article title, abstract or keywords; (“Zinc” or “Zn”) and (“mechanism” or “mechanism of action” or “action” or “effect” or “pathogenesis” or “pathology” or “physiology” or “metabolism”) and (“diabetes” or “prediabetes” or “sugar” or “glucose” or “insulin”). Results The literature search identified the following number of articles in the two databases; PubMed (n = 1799) and SciVerse Scopus (n = 1879). After removing duplicates the total number of articles included in the present review is 111. Our results show that Zinc plays an important role in β-cell function, insulin action, glucose homeostasis and the pathogenesis of diabetes and its complications. Conclusion Numerous in-vitro and in-vivo studies have shown that Zinc has beneficial effects in both type-1 and type-2 diabetes. However further randomized double-blinded placebo-controlled clinical trials conducted for an adequate duration, are required to establish therapeutic safety in humans. Electronic supplementary material The online version of this article (doi:10.1186/s40199-015-0127-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Priyanga Ranasinghe
- Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
| | - Shehani Pigera
- Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
| | | | - Prasad Katulanda
- Diabetes Research Unit, Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
| | - Godwin R Constantine
- Diabetes Research Unit, Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
| |
Collapse
|
5
|
Yoshikawa Y. [Development research of new Zn complexes with anti-diabetic effect--structure-activity-related studies by displacement of coordination atom]. YAKUGAKU ZASSHI 2014; 132:1051-5. [PMID: 23023423 DOI: 10.1248/yakushi.132.1051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The number of patients suffering from diabetes mellitus in 2007 was reported to be approximately 200 million people worldwide. Since the finding of insulinomimetic activity of Zn ion, several insulinomimetic Zn complexes have been reported. Zn complexes are expected to be useful in the treatment of diabetes mellitus. We reported that Zn complexes with coordinating sulfur atom exhibit higher insulin-mimetic activity. In this study, we investigated the pharmacological and pharmacokinetic differences between Zn(O₄) and Zn(S₂O₂) coordination environments of tropolonate-Zn complexes with antidiabetic effect. Among the tropolonate-Zn complexes with various coordination environments, di(2-mercaptotropolonato)Zn with the Zn(S₂O₂) coordination environments was found to exhibit the highest in vitro insulinomimetic activity with respect to glucose uptake in isolated rat adipocytes treated with adrenaline. In vivo experiments, di(2-mercaptotropolonato)Zn was found to exhibit potent hypoglycemic activity and improve insulin resistance in type 2 diabetic KKA(y) mice at a low orally administered daily dose. On the other hand, di(tropolonato)Zn, which has the Zn(O₄) coordination mode, had a lesser effect at the same dose. In a pharmacokinetic analysis based on the tracer method, di(2-mercaptotropolonato)Zn was found to be absorbed at a significantly slower rate with a longer half-life than di(tropolonato)Zn. These results suggest that the potent hypoglycemic activity of di(2-mercaptotropolonato)Zn with Zn(S₂O₂) coordination environments might be attributed to its long half-life.
Collapse
|
6
|
Moroki T, Yoshikawa Y, Yoshizawa K, Tsubura A, Yasui H. Morphological analysis of the pancreas and liver in diabetic KK-Aymice treated with zinc and oxovanadium complexes. Metallomics 2014; 6:1632-8. [DOI: 10.1039/c4mt00087k] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Pathological conditions for type 2 diabetes mellitus in mice are recovered after treatment with a Zn2+complex in terms of histology of organs.
Collapse
Affiliation(s)
- Takayasu Moroki
- Department of Analytical and Bioinorganic Chemistry
- Division of Analytical and Physical Chemistry
- Kyoto Pharmaceutical University
- Kyoto 607-8414, Japan
| | - Yutaka Yoshikawa
- Department of Analytical and Bioinorganic Chemistry
- Division of Analytical and Physical Chemistry
- Kyoto Pharmaceutical University
- Kyoto 607-8414, Japan
- Department of Health
| | | | - Airo Tsubura
- Department of Pathology II
- Kansai Medical University
- Hirakata 573-1010, Japan
| | - Hiroyuki Yasui
- Department of Analytical and Bioinorganic Chemistry
- Division of Analytical and Physical Chemistry
- Kyoto Pharmaceutical University
- Kyoto 607-8414, Japan
| |
Collapse
|
7
|
Sakurai H. The discovery of vanadyl and zinc complexes for treating diabetes and metabolic syndromes. Expert Opin Drug Discov 2013; 2:873-87. [PMID: 23489004 DOI: 10.1517/17460441.2.6.873] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The incidence of diabetes mellitus has increased over the decades because of lifestyle changes. The number of people with diabetes mellitus worldwide is expected to increase from 150 million to 220 million by 2010 and to 300 million by 2025. There are two main types of diabetes mellitus. Type 1 diabetes mellitus is due to the autoimmune-mediated destruction of pancreatic β cells, resulting in absolute insulin deficiency; the patients require exogenous insulin injections. Type 2 is characterized by insulin resistance and abnormal insulin secretion and the patients require exercise, diet control and/or oral hypoglycemics. However, each treatment has some adverse effects, including physical burden, formation of self-antibodies for insulin injections, the severe side effects of hypoglycemics and the discontinuation of insulin synthesis in the pancreas. To overcome these adverse effects and replace the use of these agents, the author attempted to develop new antidiabetic agents with novel structures and mechanisms. This review focuses on the authors' recent development of vanadium and zinc complexes for antidiabetic and antimetabolic syndromes.
Collapse
Affiliation(s)
- Hiromu Sakurai
- Kyoto Pharmaceutical University, Department of Analytical and Bioinorganic Chemistry, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
| |
Collapse
|
8
|
Insulino-mimetic and anti-diabetic effects of zinc. J Inorg Biochem 2013; 120:8-17. [DOI: 10.1016/j.jinorgbio.2012.11.006] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Revised: 10/26/2012] [Accepted: 11/26/2012] [Indexed: 12/24/2022]
|
9
|
Yoshikawa Y, Sakurai H, Yasui H. [Challenge of studies on the development of new Zn complexes to treat diabetes mellitus]. YAKUGAKU ZASSHI 2012; 131:925-30. [PMID: 21628979 DOI: 10.1248/yakushi.131.925] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In recent years, people all over the world have suffered from various diseases such as cancer, myocardial infarction, osteoporosis, hypertension, and diabetes mellitus (DM). Especially, DM, well-known as one of lifestyle-related diseases, has been regarded as a serious problem, because it is difficult to fully recover. The number of patients suffering from DM in 2007 was reported to be approximately 200 million people worldwide. However, insulin preparations and synthetic therapeutics, which are clinically used treatment of DM, have been associated with problems such as physical and mental pain due to daily injections and certain severe side effects, respectively. Zn, which is an essential trace element in animals and humans and plays an important role in maintenance of their lives, has been indicated to exhibit insulin-like activity. Since the finding of insulin-like effects of Zn, several Zn complexes have been proposed as a new type of anti-diabetic therapeutics which is differ from existing medicines. In this symposium, we introduce the anti-diabetic effect, complication relieving effect, and action mechanism of bis(2-mercaptopyridine-N-oxidato)Zn complex with Zn(S(2)O(2)) coordination mode.
Collapse
|
10
|
Yoshikawa Y, Murayama A, Adachi Y, Sakurai H, Yasui H. Challenge of studies on the development of new Zn complexes (Zn(opt)₂) to treat diabetes mellitus. Metallomics 2011; 3:686-92. [PMID: 21584335 DOI: 10.1039/c1mt00014d] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The number of worldwide patients suffering from diabetes mellitus (DM) is forecasted to increase over time. The development of compounds without severe side effects for type 2 DM is required not only to treat DM but also to improve the quality of life (QOL) of patients. In this paper, we have described the synthesis of novel first transition metal complexes with S2O2 coordination mode and discussed their anti-diabetic activities. Di(1-oxy-2-pyridinethiolato)Zn complex (Zn(opt)2) with Zn(S2O2) coordination mode displayed higher insulin mimetic with anti-diabetic activity, compared to the ZnCl2 or clinically used medicine (pioglitazone). In addition, Zn(opt)2 improved the insulin and adiponectine levels in the plasma. The gastrointestinal absorption of the Zn complex was found to be higher than that of ZnCl(2). Based on these results, we propose that the Zn(opt)2 complex with Zn(S2O2) coordination mode is a novel candidate for the treatment of type 2 DM; through oral administration.
Collapse
Affiliation(s)
- Yutaka Yoshikawa
- Kyoto Pharmaceutical University, 5 Nakauti-cho, Misasagi, Yamashina-ku, Kyoto, Japan.
| | | | | | | | | |
Collapse
|
11
|
Transition metal complexes of thiosemicarbazones with quinoxaline hub: an emphasis on antidiabetic property. Med Chem Res 2011. [DOI: 10.1007/s00044-011-9576-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Katoh A, Yokoyama H, Matsumura Y, Yoshikawa Y, Yasui H, Sakurai H. Synthesis of Metal Complexes with 1-Substituted 3-Hydroxy-2(1H)-pyridinethiones and Their Insulin-Mimetic Activities. HETEROCYCLES 2010. [DOI: 10.3987/com-09-11862] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
13
|
Karmaker S, Saha TK, Yoshikawa Y, Sakurai H. A Zinc(II)/Poly(γ-glutamic acid) Complex as an Oral Therapeutic for the Treatment of Type-2 Diabetic KKAyMice. Macromol Biosci 2009; 9:279-86. [DOI: 10.1002/mabi.200800190] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
14
|
Katoh A, Matsumura Y, Yoshikawa Y, Yasui H, Sakurai H. Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands. J Inorg Biochem 2008; 103:567-74. [PMID: 19162327 DOI: 10.1016/j.jinorgbio.2008.12.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2008] [Revised: 12/05/2008] [Accepted: 12/10/2008] [Indexed: 10/21/2022]
Abstract
Vanadyl sulfate (VOSO(4)) has been clinically tested in diabetic patients since 1995. Oral administrations of VOSO(4) improved the type 2 diabetic state with respect to plasma glucose, HbA(1c), and fructosamine levels. The development of toxicity by increasing the administration of VOSO(4) should be avoided. One method was the utilization of vanadyl complexes with coordination compounds that are low-toxic and low-molecular-weight ligands to enhance the permeation of the metal ion to lipid bilayer membrane. Over a decade we have focused on a variety of heterocyclic compounds as bidentate ligands for metal ions. Vanadyl and zinc(II) complexes of 1-substituted 3-hydroxy-2-methyl-4(1H)-pyridinethiones, 4,5,6-substituted 1-hydroxy-2(1H)-pyrimidinones, 4-(p-substituted)phenyl-3-hydroxythiazole-2(3H)-thiones, 3-hydroxypyrone, 1-alkyl- or 1-phenylalkyl-3-hydroxy-2(1H)-pyridinethiones, optically active 1-substituted 3-hydroxy-4(1H)-pyridinethiones, and 5-dialkylsulfonamido- or 5,7-bis(dialkylsulfonamido)-8-hydroxyquinolines were prepared, and their insulin-mimetic activities were evaluated in terms of IC(50) values which stand for a 50% inhibitory concentration of the free fatty acid release from isolated rat adipocytes. In this article, the relationship between the insulin-mimetic activity and the partition coefficient, the chirality, the substituent effect, molecular weight, the pK(a) value, and the coordination mode was discussed. In vivo blood glucose-lowering effects of the vanadyl complex with 1-hydroxy-4,6-dimethyl-2(1H)-pyrimidinone in streptozotocin (STZ)-induced diabetic rats and the zinc(II) complexes with 4-(p-chlorophenyl)thiazole- and 4-methylthiazole-2(3H)-thione in KK-A(y) mice were also discussed.
Collapse
Affiliation(s)
- Akira Katoh
- Department of Materials and Life Science, Faculty of Science and Technology, Seikei University, 3-3-1 Kitamachi, Kichijoji, Musashino-shi, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
15
|
Isomers of various species of 1-hydroxy-2-pyridinone-6-carboxylic acid, their proton dissociation and complexes with Cr(III) and Zn(II). J Mol Struct 2008. [DOI: 10.1016/j.molstruc.2008.02.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
16
|
Saha TK, Yoshikawa Y, Sakurai H. A [meso-tetrakis(4-sulfonatophenyl)porphyrinato]zinc(ii) complex as an oral therapeutic for the treatment of type 2 diabetic KKA(y) mice. ChemMedChem 2008; 2:218-25. [PMID: 17245806 DOI: 10.1002/cmdc.200600228] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We prepared and characterized [meso-tetrakis(4-sulfonatophenyl)porphyrinato]zinc(II) ([Zn(tpps)]), and investigated its in vitro insulin-mimetic activity and in vivo hypoglycemic effect in type 2 diabetic KKA(y) mice. The results were compared with those of previously proposed insulin-mimetic zinc(II) complexes and zinc sulfate (ZnSO(4)). The in vitro insulin-mimetic activity of [Zn(tpps)] was considerably better than that of bis(allixinato)zinc(II) ([Zn(alx)(2)]), bis(maltolato)zinc(II) ([Zn(mal)(2)]), bis(2-aminomethylpyridinato)zinc(II) ([Zn(2-ampy)(2)](2+)), and ZnSO(4). In particular, the order of in vitro insulin-mimetic activity of the complexes was determined to be: [Zn(tpps)]>[Zn(alx)(2)]>[Zn(mal)(2)]>[Zn(2-ampy)](2+)>ZnSO(4). [Zn(tpps)] normalized the hyperglycemia of KKA(y) mice within 21 days when administered orally at doses of 10-20 mg (0.15-0.31 mmol) Zn per kg body mass for 28 days. In addition, metabolic syndromes such as insulin resistance, the degree of renal disturbance, and the degree of liver disturbance were significantly improved in [Zn(tpps)]-treated KKA(y) mice relative to those administered with saline and ZnSO(4). The improvement in diabetes was validated by the results of oral glucose-tolerance tests and the decrease in the HbA(1c) level observed. In contrast, ZnSO(4) and the ligand H(2)tpps did not lower the elevated blood glucose level under the same experimental conditions. Based on these observations, [Zn(tpps)] is proposed to be the first orally active zinc(II)-porphyrin complex for the efficacious treatment of not only type 2 diabetes but also metabolic syndromes in animals.
Collapse
Affiliation(s)
- Tapan K Saha
- Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA.
| | | | | |
Collapse
|
17
|
Yoshikawa Y, Adachi Y, Sakurai H. A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex. Life Sci 2006; 80:759-66. [PMID: 17137606 DOI: 10.1016/j.lfs.2006.11.003] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2006] [Revised: 10/08/2006] [Accepted: 11/02/2006] [Indexed: 12/20/2022]
Abstract
In order to find orally active Zn(II) complexes that can treat diabetes mellitus (DM) at low doses, four new Zn(II)-dithiocarbamate complexes with Zn(II)-sulfur coordination bonds were prepared and their in vitro insulinomimetic activity and in vivo anti-diabetic ability were evaluated. Among the Zn(II)-dithiocarbamate complexes, the bis(pyrrolidine-N-dithiocarbamate)zinc(II) (Zn(pdc)(2)) complex was found to be the most effective in terms of inhibiting free fatty acid-release and enhancing glucose-uptake in adipocytes. After oral administration of the Zn(pdc)(2) complex to KK-A(y) mice with obesity and type 2 DM, we observed that the high blood glucose levels in the mice were lowered from approximately 500 mg/dL to 350 mg/dL within 6 days, and the effect was maintained during the administration period. Also, indicators of insulin resistance such as serum insulin, leptin, and triglyceride levels were also reduced compared with those in untreated mice. Moreover, the Zn(pdc)(2) complex improved not only the hypertension in the mice, but also the adiponectin level in the serum. On the basis of the results, the Zn(pdc)(2) complex is proposed to improve hyperglycemia and insulin resistance in type 2 DM animals on daily oral administrations.
Collapse
Affiliation(s)
- Yutaka Yoshikawa
- Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan
| | | | | |
Collapse
|